Larimar Therapeutics Files 8-K

Ticker: LRMR · Form: 8-K · Filed: May 20, 2024 · CIK: 1374690

Larimar Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyLarimar Therapeutics, Inc. (LRMR)
Form Type8-K
Filed DateMay 20, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: corporate-filing, 8-K

TL;DR

Larimar Therapeutics filed an 8-K on 5/20/24. Standard reporting.

AI Summary

Larimar Therapeutics, Inc. filed an 8-K on May 20, 2024, to report other events and financial statements. The company, formerly known as Zafgen, Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector.

Why It Matters

This filing indicates routine corporate reporting, including financial statements and other events, which is standard for publicly traded companies.

Risk Assessment

Risk Level: low — This is a routine 8-K filing for corporate reporting and does not appear to contain material non-public information that would immediately impact stock price.

Key Numbers

  • 001-36510 — SEC File Number (Identifies the company's filing with the SEC)
  • 20-3857670 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

  • Larimar Therapeutics, Inc. (company) — Registrant
  • Zafgen, Inc. (company) — Former company name
  • May 20, 2024 (date) — Date of report
  • Delaware (jurisdiction) — State of incorporation

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of May 20, 2024.

When was Larimar Therapeutics, Inc. incorporated?

Larimar Therapeutics, Inc. was incorporated in Delaware.

What was Larimar Therapeutics, Inc. formerly known as?

Larimar Therapeutics, Inc. was formerly known as Zafgen, Inc.

What is the principal executive office address for Larimar Therapeutics, Inc.?

The principal executive office is located at Three Bala Plaza East, Bala Cynwyd, Pennsylvania, 19004.

What is the SIC code for Larimar Therapeutics, Inc.?

The Standard Industrial Classification (SIC) code for Larimar Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 537 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-05-20 16:08:07

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share LRMR Nasdaq Global Market

Filing Documents

01 Other Events

Item 8.01 Other Events. Press Release On May 20, 2024, Larimar Therapeutics, Inc. (the " Company ") issued a press release announcing that the U.S. Food and Drug Administration has removed the partial clinical hold previously placed on the Company's nomlabofusp (CTI-1601) clinical program. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Investor Presentation On May 20, 2024, the Company posted on its website an updated slide presentation, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties from time to time.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Below is a list of exhibits included with this Current Report on Form 8-K. Exhibit No. Document 99.1 Press Release issued by Larimar Therapeutics, Inc. on May 20, 2024* 99.2 Larimar Therapeutics, Inc. Corporate Presentation, dated May 20, 2024* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Larimar Therapeutics, Inc. Date: May 20, 2024 By: /s/ Carole S. Ben-Maimon, M.D. Name: Carole S. Ben-Maimon, M.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.